Hay fever —lifting could come in the form of a nasal ‘molecular shield’

People with hay fever could one day take advantage of a first-of-stroke “molecular shield” that blocks pollen from the consensus lining of the nose, and the side effects seen with standard treatments are unlikely.

Hayfeber is an allergic reaction that occurs when pollen binds to molecules called IgE antibodies in the lining of the nose, mouth and eyes, triggering inflammation that results in symptoms such as sneezing and itching. Treatments included antihistamines and steroids that dampen inflammation, targets are not always effective and often have side effects, such as drowsiness.

To find an alternative, Kaissar Tabynov at the Kazakh National Agrarian Research University in Kazakhstan and his colleagues first collected blood tests from mice. They are extra closed an antibody that is not involved in allergic reactions, but still bind to the hand of the allergen in the Mugwort pollen, a major cause of hay fever. This bond then blocked the allergen from attaching to IgE antibodies in a lab bowl. “It acts as a molecular shield,” says Tabynov.

To see if this reduces irritation, the researchers induced Mugwort pollen allergies in 10 microphone by injecting them with the allergen and a chemical that trained their immune system to respond to it.

One later week, they put a small drop of fluid containing the pollen -blocking antibody in the nose of half of the mice, making it a total of three times over five days. The remaining animals got drops of saline indoor indoor. An hour after each drop was administered, the mice were exposed to the mugwort pollen at levels similar to those that people are exhibited in the peak season of the plant with the peak season, says Tabynov.

After the final drop, the mice rubbed the preventative antibody, their nossi 12 times on average over 5 minutes against 92 times in the saltwater group.

The researchers expected the antibody to reduce inflammation as they confirmed when the imaging of nose tissue samples collection from Miche at the end of the study. This also showed that the treatment had effects that connect with the body, not only that the drops we used. “Our study is the first to demonstrate that a monoclonal antibody of allergic safety can be used intrana salt to achieve both local and system protection in connection with plant pollen allergies,” says Tabynov.

Although the researchers did not measure potential side effects, they do not expect the procedure to get the opposite events seen with oral hay fever drugs because it works at the site of allergen.

“This study is an important milestone that highlights the potential of intranasal therapy for allergic rhinitis [hay fever] And helps pave the way for early clinical attempts to explore the potential of this approach in humans, “says Sayantani Sindher at Stanford University in California.

But success in micice may not be able to translate into effects in humans, and the antibody must be adapted to work in people to make sure it does not provoke its immune reaction, Tabynov says. If everything goes smooth, the team hopes to try the procedure as a nasal spray in people within the next two to three years, he says.

Such spray can also work against other types of pollen causing hay fever. “We are introducing a future where adapted antibody sprays could be available to people who are allergic to different types of pollens,” says Tabynov.